204 related articles for article (PubMed ID: 21285904)
1. Nephrotoxicity--what do we know and what don't we know?
Skinner R
J Pediatr Hematol Oncol; 2011 Mar; 33(2):128-34. PubMed ID: 21285904
[TBL] [Abstract][Full Text] [Related]
2. Chronic ifosfamide nephrotoxicity in children.
Skinner R
Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
4. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R
Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
[TBL] [Abstract][Full Text] [Related]
5. [Renal complications of anti-cancer chemotherapy].
Fillastre JP; Moulin B; Godin M; Josse S
Pathol Biol (Paris); 1986 Nov; 34(9):1013-28. PubMed ID: 3543812
[TBL] [Abstract][Full Text] [Related]
6. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.
Perazella MA; Moeckel GW
Semin Nephrol; 2010 Nov; 30(6):570-81. PubMed ID: 21146122
[TBL] [Abstract][Full Text] [Related]
9. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
10. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
11. [Nephrotoxicity induced by chemotherapy].
Di Vito R; Sirolli V; Amoroso L; Bonomini M
G Ital Nefrol; 2011; 28(3):296-304. PubMed ID: 21626498
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
13. Onco-nephrology: renal toxicities of chemotherapeutic agents.
Perazella MA
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1713-21. PubMed ID: 22879440
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity of aminoglycosides and cephalosporins in combination.
Rankin GO; Sutherland CH
Adverse Drug React Acute Poisoning Rev; 1989; 8(2):73-88. PubMed ID: 2672726
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
[TBL] [Abstract][Full Text] [Related]
16. Strategies to prevent nephrotoxicity of anticancer drugs.
Skinner R
Curr Opin Oncol; 1995 Jul; 7(4):310-5. PubMed ID: 7578377
[TBL] [Abstract][Full Text] [Related]
17. [Anticancer drug-induced nephrotoxicity].
Isnard-Bagnis C; Moulin B; Launay-Vacher V; Izzedine H; Tostivint I; Deray G
Nephrol Ther; 2005 May; 1(2):101-14. PubMed ID: 16895673
[TBL] [Abstract][Full Text] [Related]
18. Growth impairment after ifosfamide-induced nephrotoxicity in children.
Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
